BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 19381024)

  • 1. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to imatinib mesylate in chronic myeloid leukaemia.
    Melo JV; Chuah C
    Cancer Lett; 2007 May; 249(2):121-32. PubMed ID: 16949736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    Melo JV; Chuah C
    Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming drug resistance in chronic myeloid leukemia.
    Cortes J
    Curr Opin Hematol; 2006 Mar; 13(2):79-86. PubMed ID: 16456373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
    Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
    Tauchi T; Oyashiki K
    Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
    [No Abstract]   [Full Text] [Related]  

  • 8. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
    Yamamoto M; Kakihana K; Kurosu T; Murakami N; Miura O
    Cancer Genet Cytogenet; 2005 Mar; 157(2):104-8. PubMed ID: 15721630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRCircumventing imatinib resistance.
    Deininger MW; Druker BJ
    Cancer Cell; 2004 Aug; 6(2):108-10. PubMed ID: 15324693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.
    Breccia M; Muscaritoli M; Cannella L; Loglisci G; Santopietro M; Alimena G
    Leuk Res; 2010 May; 34(5):e122-4. PubMed ID: 20018374
    [No Abstract]   [Full Text] [Related]  

  • 11. Revised advice on use of imatinib for chronic myeloid leukaemia.
    Campbell K
    Nurs Times; 2003 Oct 14-20; 99(41):20-1. PubMed ID: 14603651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 13. [Origin of resistance to Imatinib mesylate: lessons learned from this experience].
    Roche-Lestienne C; Mahon FX; Preudhomme C
    Med Sci (Paris); 2004 Dec; 20(12):1125-30. PubMed ID: 15581468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
    Breccia M; Frustaci AM; Cannella L; Soverini S; Stefanizzi C; Federico V; Grammatico S; Santopietro M; Alimena G
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):195-7. PubMed ID: 19156415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
    Moser AM; Manor E; Narkis G; Kapelushnik J
    Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
    Marcucci G; Perrotti D; Caligiuri MA
    Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
    [No Abstract]   [Full Text] [Related]  

  • 17. Resistance and relapse with imatinib in CML: causes and consequences.
    Deininger M
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; BengiĆ³ R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib].
    Murase K; Matsunaga T; Takeuchi N; Fujimi A; Takimoto R; Terui T; Hirayama Y; Niitsu Y
    Rinsho Ketsueki; 2004 Sep; 45(9):1028-32. PubMed ID: 15510830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib resistance in CML.
    Volpe G; Panuzzo C; Ulisciani S; Cilloni D
    Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.